- Arecor Therapeutics
- 03 January 2024 13:44:50
Source: Sharecast
The AIM-traded firm said Dr Parris would assume her new role on 15 January.
It said that with more than two decades of experience in scientific, commercial, and government affairs within the international biopharmaceutical sector, Dr Parris would bring a wealth of expertise to her new position.
The board said she has a track record of launching transformative products and shaping markets while working with major pharmaceutical and biotechnology companies.
Before her appointment at Tetris Pharma, Dr Parris was the general manager for the UK, Netherlands, and the Nordics at Albireo Pharma.
Ipsen acquired the company in March last year, and Dr Parris reportedly played a pivotal role in establishing and developing the regional affiliate, as well as successfully launching its first product to market.
Dr Parris also had a notable history at Gilead, where she held various positions, including executive director of EMEA and global affairs regional lead.
During her tenure at Gilead, she played a crucial role in expanding patient access to treatment and spearheaded the launch of several groundbreaking drugs.
Her contributions included the development of critical launch strategies and the exploration of new commercial opportunities.
Arecor said Dr Parris holds a BSc in Biology from York University, a PhD from Leeds University, and an MBA from Henley Management College.
"Helen's proven track record in bringing products to market and growing sales will be key as we continue the roll-out of Ogluo across the UK and Europe," said chief executive officer Sarah Howell.
"Ogluo is an important treatment for people with diabetes and their caregivers that can provide them with the confidence to manage severe hypoglycaemic events and, under Helen's leadership, Tetris Pharma is even better positioned for the continued adoption of this key product in a £100m market.
"Not only will this deliver a revenue stream but a successful commercial distribution platform through Tetris Pharma is highly complementary to our existing specialty hospital products business and has significant growth potential, providing Arecor with the capability to take selected products to market in the UK and Europe."
At 1021 GMT, shares in Arecor Therapeutics were down 0.83% at 178.5p.
Reporting by Josh White for Sharecast.com.
